Literature DB >> 8314884

Nanomelic chondrocytes synthesize, but fail to translocate, a truncated aggrecan precursor.

B M Vertel1, L M Walters, B Grier, N Maine, P F Goetinck.   

Abstract

Cartilage extracellular matrix (ECM) is composed primarily of type II collagen and large, link stabilized aggregates of hyaluronic acid and chondroitin sulfate proteoglycan (aggrecan). Maturation and function of these complex macromolecules are dependent upon sequential processing events which occur during their movements through specific subcellular compartments in the constitutive secretory pathway. Failure to complete these events successfully results in assembly of a defective ECM and may produce skeletal abnormalities. Nanomelia is a lethal genetic mutation of chickens characterized by shortened and malformed limbs. Previous biochemical studies have shown that cultured nanomelic chondrocytes synthesize a truncated aggrecan core protein precursor that disappears with time; however, the protein does not appear to be processed by the Golgi or secreted. The present study investigates the intracellular trafficking of the defective aggrecan precursor using immunofluorescence, immunoelectron microscopy and several inhibitors. Results indicate that nanomelic chondrocytes assemble an ECM that contains type II collagen, but lacks aggrecan. Instead, aggrecan precursor was localized intracellularly, within small cytoplasmic structures corresponding to extensions of the endoplasmic reticulum (ER). At no time were precursor molecules observed in the Golgi. In contrast, normal and nanomelic chondrocytes exhibited no difference in the intracellular or extracellular distribution of type II procollagen. Therefore, retention of the aggrecan precursor appears to be selective. Incubation of chondrocytes at 15 degrees C resulted in the retention and accumulation of product in the ER. After a return to 37 degrees C, translocation of the product to the Golgi was observed for normal, but not for nanomelic, chondrocytes, although the precursors disappeared with time. Ammonium chloride, an inhibitor of lysosomal function, had no effect on protein loss, suggesting that the precursor was removed by a non-lysosomal mechanism, possibly by ER-associated degradation. Based on these studies, we suggest that nanomelic chondrocytes are a useful model for examining cellular trafficking and sorting events and the processes by which abnormal products are targeted for retention or degradation. Further investigations should provide insight into the mechanisms underlying chondrodystrophies and other related diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314884     DOI: 10.1242/jcs.104.3.939

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  15 in total

1.  Immortalized, cloned mouse chondrocytic cells (MC615) produce three different matrix proteoglycans with core-protein-specific chondroitin/dermatan sulphate structures.

Authors:  R Kokenyesi; J E Silbert
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

2.  Conserved basic residues in the C-type lectin and short complement repeat domains of the G3 region of proteoglycans.

Authors:  N C Brissett; S J Perkins
Journal:  Biochem J       Date:  1998-01-15       Impact factor: 3.857

3.  Species-specific alternative splicing of the epidermal growth factor-like domain 1 of cartilage aggrecan.

Authors:  C Fülöp; G Cs-Szabó; T T Glant
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

4.  A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis.

Authors:  Lindsay Gleghorn; Rajkumar Ramesar; Peter Beighton; Gillian Wallis
Journal:  Am J Hum Genet       Date:  2005-07-22       Impact factor: 11.025

5.  Structure of the human aggrecan gene: exon-intron organization and association with the protein domains.

Authors:  W B Valhmu; G D Palmer; P A Rivers; S Ebara; J F Cheng; S Fischer; A Ratcliffe
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

6.  The chondrodystrophy, nanomelia: biosynthesis and processing of the defective aggrecan precursor.

Authors:  B M Vertel; B L Grier; H Li; N B Schwartz
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

7.  Roles of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion.

Authors:  C Kiani; V Lee; L Cao; L Chen; Y Wu; Y Zhang; M E Adams; B B Yang
Journal:  Biochem J       Date:  2001-02-15       Impact factor: 3.857

8.  A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans.

Authors:  Eva-Lena Stattin; Fredrik Wiklund; Karin Lindblom; Patrik Onnerfjord; Björn-Anders Jonsson; Yelverton Tegner; Takako Sasaki; André Struglics; Stefan Lohmander; Niklas Dahl; Dick Heinegård; Anders Aspberg
Journal:  Am J Hum Genet       Date:  2010-02-04       Impact factor: 11.025

9.  Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage.

Authors:  J Dudhia; C M Davidson; T M Wells; D H Vynios; T E Hardingham; M T Bayliss
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

10.  The synthesis and secretion of versican isoform V3 by mammalian cells: A role for N-linked glycosylation.

Authors:  Ingrid A Harten; Gernot Kaber; Kiran J Agarwal; Inkyung Kang; Sean Reyes Ibarrientos; Gail Workman; Christina K Chan; Mary P Nivison; Nadine Nagy; Kathleen R Braun; Michael G Kinsella; Mervyn J Merrilees; Thomas N Wight
Journal:  Matrix Biol       Date:  2020-01-27       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.